Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation

Blood

Volumn 92, Issue 5, 1998, Pages 1471-1490

  Guillaume, Thierry ^a   Rubinstein, Daniel B ^b   Symann, Michel ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 2; INTERLEUKIN 7; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; AUTOTRANSPLANTATION; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL REGENERATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0032170052     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.5.1471     Document Type: Review

References (247)

1. Horowitz MM: New IBMTR/ABMTR slides summarize current use and outcome of allogeneic and autologous transplants. IBMTR News Lett 2:1, 1995
2. Philip Th, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn J-Y, Harousseau J-L, Coiffier B, Biron P, Mandelli F, Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540, 1995
3. Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S, for the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEME) leukemia cooperative groups: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217, 1995
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91, 1996
5. Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiels J, Beauduin M, Doyen C, Weynants P, Longueville J, Prignot J: Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung: A randomized study. J Clin Oncol 5:1864, 1987
6. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483, 1995
7. Lum LG: The kinetics of immune reconstitution after human marrow transplantation. Blood 69:369, 1987
8. Atkinson K: Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 5:209, 1990
9. Burrows PD, Cooper MD: B cell development and differentiation. Curr Opin Immunol 9:239, 1997
10. Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A: B cell reconstitution after human bone marrow transplantation: Recapitulation of ontogeny? Bone Marrow Transplant 12:387, 1993
11. Bengtsson M, Smedmyr B, Festin R, Öberg G, Simonsson B, Tötterman TH: B lymphocyte regeneration in marrow and blood after autologous bone marrow transplantation: Increased numbers of B cells carrying activation and progression markers. Leuk Res 13:791, 1989
12. Small TN, Keever CA, Weiner-Fedus S, Heller G, O'Reilly RJ, Flomenberg N: B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: A recapitulation of normal B-cell ontogeny. Blood 76:1647, 1990
13. Leitenberg D, Rappeport JM, Smith BR: B-cell precursor bone marrow reconstitution after bone marrow transplantation. Am J Clin Pathol 102:231, 1994
14. Uckun FM, Haisig S, Ledbetter JA, Fidler P, Myers DE, Kuebelbeck V, Weisdorf D, Gajl-Peczalska K, Kersey JH, Ramsay KC: Developmental hierarchy during early human B cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B cell precursors by an anti-CD 19 pan B cell immunotoxin containing pokeweed antiviral protein. Blood 79:3369, 1992
15. Pedrazzini A, Freedman AS, Andersen J, Heflin L, Anderson K, Takvorian T, Canellos GP, Whitman J, Coral F, Ritz J, Nadler LM: Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: Phenotypic reconstitution and B-cell function. Blood 74:2203, 1989
16. Fumoux F, Guigou V, Blaise D, Maraninchi D, Fougereau M, Schiff C: Reconstitution of human immunoglobulin VH repertoire after bone marrow transplantation mimics B-cell ontogeny. Blood 81:3153, 1993
17. Storek J, King L, Ferrara S, Marcelo D, Saxon A, Braun J: Abundance of a restricted fetal B cell repertoire in marrow transplant recipients. Bone Marrow Transplant 14:783, 1994
18. Suzuki I, Milner EC, Glas AM, Hufnagle WO, Rao SP, Pfister L, Nottenburg C: Immunoglobulin heavy chain variable region gene usage in bone marrow transplant recipients: Lack of somatic mutation indicates a maturational arrest. Blood 87:1873, 1996
19. Saxon A, Mitsuyasu R, Stevens R, Champlin RE, Kimata H, Gale RP: Designed transfer of specific immune responses with bone marrow transplantation. J Clin Invest 78:959, 1986
20. Wimperis JZ, Brenner MK, Prentice HG, Reittie JE, Karayannis P, Griffiths PD, Hoffbrand AV: Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1:339, 1986
21. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, Strauss N, Parag G, Naparstek E, Ravid Z, Or R, Slavin S, Zakay-Rones Z: Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 11:1, 1993
22. Ilan Y, Nagler A, Adler R, Naparstek E, Or R, Slavin S, Brautbar C, Shouval D: Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 18:246, 1993
23. Lane HC, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, Masur H, Leitman SF, Klein HG, Steis RG, Longo DL, Fauci AS: Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med 113:512, 1990
24. Molrine DC, Guinan EC, Antin JH, Wheeler C, Parsons SK, Weinstein HJ, McGarigle C, Blanding P, Phillips NR, Ciamarra A, George S, Ambrosino DM: Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplant 17:1149, 1996
25. Witherspoon RP, Lum LG, Storb R, Thomas ED: In vitro regulation of immunoglobulin synthesis after human marrow transplantation. II. Deficient T and non T-lymphocyte function within 3-4 months of allogeneic, syngeneic, or autologous marrow grafting for hematologic malignancy. Blood 59:844, 1982
26. Kiesel S, Pezzutto A, Moldenhauer G, Haas R, Körbling M, Hunstein W, Dörken B: B-cell proliferative and differentiative responses after autologous peripheral blood stem cell or bone marrow transplantation. Blood 72:672, 1988
27. Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP, Schlossmah SF: Anti-B1 monoclonal and complement treatment in autologous bone marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet 2:427, 1984
28. Armitage RJ, Goldstone AH, Richards JDM, Cawley JC: Lymphocyte function after autologous bone marrow transplantation (BMT): A comparison with patients treated with allogeneic BMT and with chemotherapy only. Br J Haematol 63:637, 1986
29. Rocha B, Guy-Grand D, Vassalli P: Extrathymic T cell differentiation. Curr Opin Immunol 7:235, 1995
30. Dejbakhsh-Jones S, Jerabek L, Weissman IL, Strober S: Extrathymic maturation of αβ T cells from hemopoietic stem cells. J Immunol 155:3338, 1995
31. Sugita K, Soiffer RJ, Murray C, Schlossman SF, Ritz J, Morimoto C: The phenotype and reconstitution of immunoregulatory T cell subsets after T-cell-depleted allogeneic and autologous bone marrow transplantation. Transplantation 57:1465, 1994
32. Olsen GA, Gockerman JP, Bast RC, Borowitz M, Peters WP: Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. Transplantation 46:57, 1988
33. Bengtsson M, Tötterman TH, Smedmyr B, Festin R, Öberg G, Simonsson B: Regeneration of functional and activated NK and T subset cells in the marrow and blood after autologous bone marrow transplantation: A prospective phenotypic study with 2/3-color FACS analysis. Leukemia 3:68, 1989
34. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Horowitz ME, Magrath IT, Shad AT, Steinberg SM, Wexler LH, Gress RE: Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332:143, 1995
35. Kast WM, De Waal LP, Melief CJM: Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC restricted T cells. J Exp Med 160:1752, 1984
36. Steinmann GG, Klaus B, Müller-Hermelink H-K: The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study. Scand J Immunol 22:563, 1985
37. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Magrath IT, Wexler LH, Dimitrov DS, Gress RE: Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 89:3700, 1997
38. Azuma M, Phillips JH, Lanier LL: CD28- T lymphocytes. Antigenic and functional properties. J Immunol 150:1147, 1993
39. Storek J, Witherspoon RP, Storb R: T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 16:413, 1995
40. Weaver CH, Longin K, Buckner CD, Bensinger W: Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 13:411, 1994
41. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H: Improved immune reconstitution after allotransplantation of peripheral blood stem cell instead of bone marrow. Blood 88:2275, 1996
42. Hénon PR, Liang H, Beck-Wirth G, Eisenmann JC, Lepers M, Wunder E, Kandel G: Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 9:285, 1992
43. Koehne G, Zeller W, Stockschlaeder M, Zander AR: Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19:149, 1997
44. Ho AD, Maruyama M, Maghazachi A, Mason JR, Glück S, Corringham RET: Soluble CD4, soluble CD8, Soluble CD25, lymphopoietic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation. Blood 84:3550, 1994
45. Kiesel S, Pezzutto A, Körbling M, Haas R, Schulz R, Hunstein W, Dörken B: Autologous peripheral blood stem cell transplantation: Analysis of autografted cells and lymphocyte recovery. Transplant Proc 21:3084, 1989
46. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL, Mills KC, Thomas ML, Pirruccello SJ, Letheby BA, Arneson MA, Jackson JD: Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 17:101, 1996
47. Talmadge JE, Reed E, Ino K, Kessinger A, Kuszynski C, Heimann D, Varney M, Jackson J, Vose JM, Bierman PJ: Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 19:161, 1997
48. Ashihara E, Shimazaki C, Yamagata N, Hirata T, Okawa K, Oku N, Goto H, Inaba T, Fujita N, Nakagawa M: Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation:Two-color flow cytometric analysis. Bone Marrow Transplant 13:377, 1994
49. Vilmer E, Triebel F, David V, Rabian C, Schumpp M, Leca G, Degos L, Hercend T, Sigaux F, Bensussan A: Prominent expansion of circulating lymphocytes bearing γ T-cell receptors, with preferential expression of variable γ genes after allogeneic bone marrow transplantation. Blood 72:841, 1988
50. + T-cell receptor γ/δ T cells early after bone marrow transplantation. Blood 78:1875, 1991
51. Villers D, Milpied N, Gaschet J, Davodeau F, Hallet M-M, Bonneville M, Vié H: Alteration of the T cell repertoire after bone marrow transplantation. Bone Marrow Transplant 13:19, 1994
52. + T cells with restricted T-cell receptor β chain variability after bone marrow transplantation. Blood 83:587, 1994
53. Gaschet J, Denis C, Milpied N, Haltet M-M, Romagné F, Necker A, Vivien R, David-Ameline J, Davodeau F, Bonneville M, Vié H: Alterations of T cell repertoire after bone marrow transplantation: Characterization of over-represented subsets. Bone Marrow Transplant 16:427, 1995
54. Krangel MS, Yssel H, Brocklehurst C, Spits H: A distinct wave of human T cell receptor γ/δ lymphocytes in early life thymus: Evidence for controlled gene rearrangement and cytokine production. J Exp Med 172:847, 1990
55. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson FW, Ihle JN: Gene marking to determine whether autologous marrow infusion restores long-term haematopoiesis in cancer patients. Lancet 342:1134, 1993
56. Butturini A, Seeger RC, Gale RP: Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood 68:954, 1986
57. Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E: Analysis of T-cell population after allogeneic bone marrow transplantation: Significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 87:3984, 1996
58. Kato S, Yabe H, Yabe M, Kimura M, Ito M, Tsuchida F, Tsuji K, Takahashi M: Studies on transfer of varicella-zoster-virus specific T cell immunity from bone marrow donor to recipient. Blood 75:806, 1990
59. Rouleau M, Senik A, Leroy E, Vernant JP: Long-term persistence of transferred PPD-reactive T cells after allogeneic bone marrow transplantation. Transplantation 55:72, 1993
60. Müller-Hermelink HK, Sale GE, Borisch B, Storb R: Pathology of the thymus after allogeneic bone marrow transplantation in man. Am J Pathol 129:242, 1987
61. Mackall CL, Granger L, Sheard MA, Cepeda R, Gress RE: T-cell regeneration after bone marrow transplantation: Differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 82:2585, 1993
62. Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA, Gress RE: Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 156:4609, 1996
63. Miller RA, Daley J, Ghalie R, Kaizer H: Clonal analysis of T-cell deficiencies in autotransplant recipients. Blood 77:1845, 1991
64. Cayeux S, Meuer S, Pezzutto A, Körling M, Haas R, Schulz R, Dörken B: T-cell ontogeny after autologous bone marrow transplantation: Failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4+ and CD8+ cells even in the presence of exogeneous IL-2. Blood 74:2270, 1989
65. Katsanis E, Anderson PM, Filipovich AH, Hasz DE, Rich ML, Loeffler CM, Ochoa AC, Weisdof DJ: Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. Blood 78:1286, 1991
66. Sugita K, Nojima Y, Tachibana K, Soiffer RJ, Murray C, Schlossman SF, Ritz J, Morimoto C; Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation. J Clin Invest 94:481, 1994
67. Lum LG, Joshi ID, Galoforo SC, Abella E, Karanes C, Ratanatharathorn V, Schultz KR, Uberti JP, Sensenbrenner LL, Ledbetter JA, June CH: Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients. Bone Marrow Transplant 12:565, 1993
68. Cayeux S, Meuer S, Pezzutto A, Körbling M, Haas R, Schulz R, Dörken B: Allogeneic mixed lymphocyte reactions during a second round of ontogeny: Normal accessory cells did not restore defective interleukin-2 (IL-2) synthesis in T cells but induced responsiveness to exogenous IL-2. Blood 74:2278, 1989
69. Weite K, Keever CA, Levick J, Bonilla MA, Merluzzi VJ, Mertelsmann R, Evans R, O'Reilly RJ: Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow. Blood 70:1595, 1987
70. Mielcarek M, Martin PJ, Torok-Storb B: Suppression of alloantigen-induced T-cell prolidferation by CD14+ cels derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 89:1629, 1997
71. Ageitos AG, Ino K, Ozerol I, Tarantolo S, Heimann DG, Talmadge JE; Restoration of T and NL cell function in GM-CSF mobilized stem cell products from breast cancer patients by monocyte depletion. Bone Marrow Transplant 20:117, 1997
72. Reusser P, Attenhofer R, Hebart H, Helg C, Chapuis B, Einsele H: Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood 89:3873, 1997
73. Nolte A, Buhmann R, Straka C, Emmerich B, Hallek M: Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 21:909, 1998
74. Reittie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Prentice HG, Brenner MK: Endogenously generated killer cells circulate after autologous and allogeneic marrow transplantation but not chemotherapy. Blood 73:1352, 1989
75. Higuchi CM, Thompson JA, Cox T, Lindgren CG, Buckner CD, Fefer A: Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 49:5509, 1989
76. Neubauer MA, Benyunes MC, Thomson JA, Bensinger WI, Lindgren CG, Buckner CD, Fefer A: Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 13:311, 1994
77. Fegan C, Thomas H, Bailey-Wood R, Coleman S, Philips S, Hoy T, Wittaker JA: In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation. Bone Marrow Transplant 16:277, 1995
78. Pavletic Z, Benyunes MC, Thompson JA, Lindgren CG, Massumoto C, Alderson MR, Buckner CD, Fefer A: Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy. Exp Hematol 21:1371, 1993
79. Guillaume T, Sekhavat M, Rubinstein DB, Hamdan O, Leblanc P, Symann ML: Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin, and lack of evidence for a role for IL-10 in delayed immune reconstitution. Cancer Res 54:3800, 1994
80. Bosly AE, Staquet PJ, Doyen CM, Chatelain BJ, Humblet YP, Symann ML: Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation. Exp Hematol 15:1048, 1987
81. Hanenberg H, Dilloo D, Laws H-J, Zessack N, Heyll A, Burdach S: Time course of interferon-γ production deficiency after autologous and allogeneic stem cell transplantation for malignancies. Exp Hematol 23:1543, 1995
82. Anderson KC, Ritz J, Takvorian T, Coral F, Daley H, Gorgone BC, Freedman AS, Canellos GP, Schlossman SF, Nadler LM; Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood 69:597, 1987
83. Bosly A, Guillaume T, Brice P, Humblet Y, Staquet P, Doyen C, Chatelain B, Franks C, Gisselbrecht C, Symann M: Effects of escalating doses of recombinant human interleukin-2 (r-IL-2) in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Exp Hematol 20:962, 1992
84. Roberts MM, To LB, Gillis D, Mundy J, Rawling C, Ng K, Juttner CA: Immune reconstitution following peripheral blood stem cell transplantation, autologous marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 12:469, 1993
85. Trinchieri G: lnterleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper type 1 and cytotoxic lymphocytes. Blood 84:4008, 1994
86. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor and anti-metastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223, 1993
87. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153:1697, 1994
88. Soiffer R, Robertson M, Murray C, Cochran K, Ritz J: Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 82:2790, 1993
89. Guillaume T, Kubin M, Sekhavat M, Rubinstein DB, Trinchieri G, Symann M: Peripheral blood mononuclear cells derived from patients undergoing autologous hematopoietic stem cell transplantation produce and respond to IL-12. Bone Marrow Transplant 18:733, 1996
90. Shu U, Kiniwa M, Wu CY, Maliszewski C, Vezzio N, Hakimi J, Gately M, Delespesse G: Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol 25:1125, 1995
91. Lindgren CG, Thompson JA, Robinson N, Keeler T, Gold PJ, Fefer A: Interleukin-12 induces cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants. Bone Marrow Transplant 19:867, 1997
92. Dorshkind K, Pollack SB, Bosma MJ, Phillips RA: Natural killer cells are present in mice with severe combined immunodeficiency (SCID). J Immunol 134:3798, 1985
93. Hackett J, Bosma GC, Bosma MJ, Bennett M, Kumar V: Transplantable progenitors of natural killer cells are distinct from those of T and B lymphocytes. Proc Natl Acad Sci USA 93:3427, 1986
94. Wahren B, Gahrton G, Linde A, Ljungman P, Lonnqvist B, Ringden O, Sundqvist VA: Transfer and persistence of viral antibody-producing cells in bone marrow transplantation. J Infect Dis 150:358, 1984
95. Gratama JW, Verdonck LF, van der Linden JA, van Heugten JG, Kreeft HAJG, D' Amaro J, Zwaan FE, de Gast GC: Cellular immunity to vaccinations and herpes-virus infections after bone marrow transplantation. Transplantation 41:719, 1986
96. Meyers JD, Flournoy N, Thomas ED: Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 142:338, 1980
97. Wade JC, Day LM, Crowley JJ, Meyers JD: Recurrent infection with herpes simplex virus after marrow transplantation: Role of the specific immune response and acyclovir treatment. J Infect Dis 149:750, 1980
98. Reusser P, Fisher LD, Buckner CD, Thomas ED, Meyers JD: Cytomegalovirus infection after autologous bone marrow transplantation: Occurrence of cytomegalovirus disease and effect on engrafment. Blood 75:1888, 1990
99. Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R: Herpes zoster infection after autologous bone marrow transplantation. Blood 74:1424, 1989
100. Whimbey E, Elting LS, Couch RB, Lo W, Williams L, Champlin RE, Bodey GP: Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 13:437, 1994
101. Boeckh M, Gooley TA, Reusser P, Buckner CD, Bowden RA: Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 172:939, 1995
102. Mazumder A, Rosenberg SA: Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J Exp Med 159:495, 1984
103. Rosenberg SA, Mulé J, Spiess P, Reicher CM, Schwartz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 . J Exp Med 161:1169, 1985
104. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485, 1985
105. Atkins MB: Interleukin-2 therapy: A decade of slow but steady progress. Cancer J Sci Am 2:73, 1996
106. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H: Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68:938, 1986
107. Lotzova E, Savary CA, Herberman RB: Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J Immunol 138:2718, 1987
108. Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Fomi G, Foa R: In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 2:50, 1988
109. Ackerstein A, Kedar E, Slavin S: Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood 78:1212, 1991
110. Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK: Effect of recombinant interleukin-2 on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood 74:2335, 1989
111. Blaise D, Olive D, Stoppa AM, Viens P, Pourreau C, Lopez M, Attal M, Jasmin C, Monges G, Mawas C, Mannoni P, Palmer P, Franks C, Philip T, Maraninchi D: Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 76:1092, 1990
112. Heslop H, Duncombe AS, Reittie J, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Hoffbrand AV, Brenner MK: Interleukin-2 infusion after autologous bone marrow transplantation of chemotherapy enhances hemopoietic regeneration. Transplant Proc 23:1704, 1991
113. Higuchi C, Thompson JA, Petersen FB, Buckner CD, Fefer A: Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematological malignancies. Blood 77:2561, 1991
114. Soiffer R, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J: Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79:517, 1992
115. Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson JA, Petersen FB, Fefer A: Preliminary report. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 12:159, 1993
116. Hamon MD, Prentice HG, Gottlieb DJ, Macdonald ID, Cunningham JM, Smith OP, Gilmore M, Gandhi L, Collis C: Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 11:399, 1993
117. Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A: Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: A feasibility trial. Bone Marrow Transplant 16:283, 1995
118. Fefer A, Benyunes MC, Massumoto C, Higuchi C, York A, Buckner CD, Thompson JA: Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 20:41, 1993
119. Weisdorf DJ, Anderson PM, Blazar BR, Uckun FM, Kersey JH, Ramsay NKC: Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia: A phase T study. Transplantation 55:61, 1993
120. Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant JP, Sauvage C, Troussard X, Nedellec G, Pico J, Huguet F, Stoppa AM, Broustet A, Sotto JJ, Pris J, Maraninchi D, Reiffers J for the BGMT Group: Consolidation treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 86:1619, 1995
121. Robinson N, Benyunes MC, Thomson JA, York A, Petersdorf S, Press O, Lindgren C, Chauncey T, Buckner CD, Bensinger WI, Appelbaum FR, Fefer A: Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: A phase I/II study. Bone Marrow Transplant 19:435, 1997
122. Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowsky J, Radford J Jr, Burns LJ: Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant 3:34, 1997
123. Blaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C, Molina L, Nedellec G, Vernant JP, Legros M, Gabus R, Huguet F, Brandely M, Hercend T, Olive D, Maraninchi D: The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma 25:469,1997
124. Blaise D, Attal M, Reiffers J, Stoppa AM, Huguet F, Marit G, Molina L, Bellanger C, Pico JL, Gabus R, Brandely M, Hercend T, Maraninchi D: Randomized study of interleukin 2 (RIL2) after autologous bone marrow transplantation (BMT) in 130 patients with acute leukemia (AL) in first complete remission (CR1): Results of a multicentric trial with a 5 year follow up. Blood 90:113a, 1997 (abstr, suppl 1)
125. Valteau-Couanet D, Rubie H, Meresse V, Farace F, Brandely M, Hartmann O: Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant 16:515, 1995
126. Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK: Interleukin 2 infusion induces haematopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol 77:237, 1991
127. López-Jiménez, Pérez-Oteyza, Muñoz, Parra C, Villalón L, Ramos P, Maldonado M, García-Laraña, Otheo E, Roldán E, García-Avello A, Odriozola J: Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: Results of a prospective, non-randomized study. Bone Marrow Transplant 19:429, 1997
128. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, Meyer JD, Davison BL: Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 180:1955, 1994
129. von Freeden-Jerry U, Vierira P, Lucian LA, McNeil T, Burdach SE, Murray R: Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a non redundant cytokine. J Exp Med 181:1519, 1995
130. Boerman OC, Gregorio TA, Grzegorzewski KJ, Faltynek CR, Kenny JJ, Wiltrout RH, Komschlies KL: Recombinant human IL-7 administration in mice affects colony-forming units-spleen and lymphoid precursors cell localization and accelerates engraftment of bone marrow transplants. J Leukoc Biol 58:151, 1995
131. Bolotin E, Smogorzewska M, Smith S, Widmer M, Weinberg K: Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood 88:1887, 1996
132. Abdul-Hai A, Reuven O, Slavin S, Friedman G, Weiss L, Matsa D, Ben-Yehuda A: Stimulation of immune reconstitution by interleukin-7 after syngeneic bone marrow transplantation in mice. Exp Hematol 24:1416, 1996
133. Agah R, Malloy B, Kerner M, Mazumder A: Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation. J Immunol 143:3093, 1989
134. Agah R, Malloy B, Kerner M, Girgis E, Bean P, Twomey P, Mazumder A:
135. Charak BS, Brynes RK, Groshen S, Chen S-C, Mazumder A: Bone marrow transplantation with interleukin-2 activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 76:2187, 1990
136. Charak BS, Agah R, Mazumder A: Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: Application in bone marrow transplantation. Blood 81:3474, 1993
137. Charak BS, Agah R, Brynes RK, Chogyoji M, Groshen S, Chen SC, Mazumder A: Interleukin-2 (IL-2) and IL-2-activated bone marrow in transplantation: Evaluation from a clinical perspective. Bone Marrow Transplant 9:479, 1992
138. Adler A, Chervenick PA, WhitesideTL, Lotzova E, Herberman RB: Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71:706, 1988
139. Keever CA, Pekle K, Gazzola MV, Collins NH, Gillio A: NK and LAK activities from marrow progenitors. I. The effects of interleukin-2 and interleukin-1. Cell Immunol 126:211, 1990
140. Klingemann H-G, Deal H, Reid D, Eaves CJ: Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp Hematol 21:1263, 1993
141. Margolin KA, Wright C, Forman SJ: Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells. Leukemia 11:723, 1997
142. Meehan KR, Verma UN, Frankel SR, Rajagopal C, Cahill R, Arun-Killic B, Jenson M, Oquendo C, Mazumder A: Immunotherapy with IL-2 and α-IFN after PBSC transplantation for women with breast cancer. Blood 86:387a, 1995 (abstr, suppl 1)
143. Areman EM, Mazumder A, Kotula PL, Verma UN, Rajagopal C, Hancock S, Guevarra C, Djahanmir M, Sacher RA, Meehan KR: Hematopoietic potential of IL-2-cultured peripheral blood stem cells from breast cancer patients. Bone Marrow Transplant 18:521, 1996
144. Miller JS, Klingsporn S, Lund J, Perry EH, Verfaillie C, McGlave P: Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant 14:555, 1994
145. Miller JS, Verfaillie C, McGlave PB: Expansion and activation of human natural killer cells as therapy for autologous transplantation. Prog Clin Biol Res 389:39, 1994
146. Charak BS, Brynes RK, Katsuda S, Groshen S, Chen S-C, Mazumder A: Induction of graft versus leukemia effect in bone marrow transplantation: Dosage and time schedule dependency of interleukin-2 therapy. Cancer Res 51:2015, 1991
147. Klingemann H-G, Eaves CJ, Barnett MJ, Eaves AC, Hogge DE, Nantel SH, Reece E, Sheperd JD, Sutherland HJ, Phillips GL: Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 14:389,1994
148. Beaujean F, Bernaudin F, Kuentz M, Lemerle S, Cordonnier C, Le Forestier C, Reinert P, Duedari N, Brandely M, Vernant J-P: Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia. Bone Marrow Transplant 15:691, 1995
149. Margolin KA, Negrin RS, Wong KK, Chatterjee S, Wright C, Forman SJ: Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 157:231, 1997
150. Glazier AD, Tutschka PJ, Farmer ER, Santos GW: Graft-versus-host disease in cyclosporine A treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med 158:1, 1983
151. Hess AD, Horwitz L, Beshorner WE, Santos GW: Development of graft-versus-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T-lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 161:718, 1985
152. Shinozawa T, Beshorner WE, Hess AD: The thymus and prolonged administration of cyclosporine. Irreversible immunopathological changes associated with autologous pseudo-graft-versus-host disease. Transplantation 50:106, 1990
153. Sorokin R, Kimura H, Schroder K, Wilson DH, Wilson DB: Cyclosporine-induced autoimmunity. Conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J Exp Med 164:1615, 1986
154. Jenkins MK, Schwartz RH, Pardoll DM: Effects of cyclosporine A on T cell development and clonal deletion. Science 241:1655, 1988
155. Fisher AC, Beshorner WE, Hess AD Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-versus-host disease. J Exp Med 169:1031, 1989
156. Fisher AC, Laulis MK, Horwitz L, Beshorner WE, Hess AD: Host resistance to cyclosporine induced syngeneic graft-versus-host disease. J Immunol 143:827, 1989
157. Beshorner WE, Suresch DL, Shinozawa T, Hess AD: Influence of irradiation and age on the CsA-induced thymic immunopathology. Transplant Proc 20:1072, 1988 (suppl 3)
158. Hess AD, Horwitz LR, Laulis MK: Cyclosporin induced syngeneic graft-versus-host disease: Prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens. Clin Immunol Immunopathol 69:341, 1993
159. Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ, Kennedy MJ: Specificity and antitumor activity of effector T lymphocytes in autologous graft-vs-host disease: Role of the MHC class II invariant chain peptide. Blood 89:2203, 1997
160. Geller RB, Esa AH, Beshorner WE, Frondoza CG, Santos GW, Hess AD: Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 74:1165, 1989
161. Bryson JS, Jennings CD, Caywood BE, Kaplan AM: Strain specificity in the induction of syngeneic graft-versus-host disease in mice. Transplantation 51:911, 1991
162. Charak BS, Agah R, Mazumder A: Synergism of interleukin-2 and cyclosporine A in induction of a graft-versus-tumor effect without graft-versus-host disease after syngeneic bone marrow transplantation. Blood 80:179, 1992
163. Hooton JWL, Miller CL, Helgason CD, Bleackley RC, Gillis S, Paetkau V: Development of pretoxic T cells in cyclosporine-suppressed mixed lymphocyte reactions. J Immunol 144:816, 1990
164. Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB, Piantadosi S, Santos GW: Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1:754, 1989
165. Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Altomonte V, Hess AD, Santos GW: Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 79:3031, 1992
166. Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM, Davidson NE: Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 11:478, 1993
167. Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess DA, Altomonte V, Huelskamp AM, Davidson NE: Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 12:249, 1994
168. Ratanatharathorn V, Uberti J, Karanes C, Lum LG, Abella E, Dan ME, Hussein M, Sensenbrenner LL: Phase I study of alpha-interferon augmentation of cyclosporine-induced graft-versus-host disease in recipients of autologous bone marrow transplantation. Bone Marrow Transplant 13:625, 1994
169. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R: Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 15:667, 1997
170. Gryn J, Johnson E, Goldman N, Devereux L, Grana G, Hageboutros A, Fernandez E, Constantinou C, Harrer W, Viner E, Goldberg J: The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Bone Marrow Transplant 19:221, 1997
171. Long GS, Cramer DV, Harnaha JB, Hiserodt JC: Lymphokine-activaied killer (LAK) cell purging of leukemic bone marrow: Range of activity against different hematopoietic neoplasms. Bone Marrow Transplant 6:169, 1990
172. Schlegel PG, Schmidt-Wolf G, Schmidt-Wolf IGH, Kwak LW, Chao NJ: Lymphokine-activated killer cells activity against autologous lymphoma cells following bone marrow transplantation. Cancer Res Ther Control 3:145, 1993
173. Gambacorti-Passerini C, Rivoltini L, Supino R, Rodolfo M, Radrizzani M, Fossati G, Parmiani G: Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. Cancer Res 48:2372, 1988
174. Lister J, Rybka WB, Donnenberg AD, de Magalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whitheside TL:Autologous peripheral blood stem cell transplantation and adoptive with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1:607, 1995
175. Schmidt-Wolf IGH, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21:1673, 1993
176. Lu PH, Negrin RS: A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153:1687, 1994
177. Schmidt-Wolf IGH, Lefterova P, Johnston V, Shefold C, Csipai M, Mehta B, Tsuruo T, Huhn D, Negrin RS: Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 169:85, 1995
178. Schmidt-Wolf IGH, Negrin RS, Kiem H, Blume KG, Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent anti-tumor cell activity. J Exp Med 174:139, 1991
179. Cesano A, Visonneau S, Cioé L, Clark S, Rovera G, Santoli D: Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J Clin Invest 94:1076, 1994
180. Cesano A, Visonneau S, Jeglum KA, Owen J, Wilkinson K, Carner K, Reese L, Santoli D: Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res 56:3021, 1996
181. Visonneau S, Cesano A, Torosian MH, Santoli D: Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice. Clin Cancer Res 3:1491, 1997
182. Gong J-H, Maki G, Kingemann H-G: Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652, 1994
183. Robertson MJ, Cochran KJ, Cameron C, Le J-M, Tantravahi R, Ritz J: Characterization of a cell line, NKL, derived from an aggressive natural killer cell leukemia. Exp Hematol 24:406, 1996
184. Riddell SR, Greenberg PD: Cellular adoptive immunotherapy after bone marrow transplantation. Cancer Treat Res 76:337, 1995
185. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cells clones. Science 257:238, 1992
186. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038, 1995
187. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
188. Nowell PC, Hungerford DA: A minute chromosome in human chonic granulocytic leukemia. Science 132:1497, 1960
189. Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON:Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 235:85, 1987
190. Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpas M, Trujillo JM, Blick M, Beran M, Gutterman JU: A novel c-abl protein product in Philadelphia-positive acute lymphobiastic leukaemia. Nature 325:631, 1987
191. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A: The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347:558, 1990
192. Tsujimoto Y, Finger LR, Yunis, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the (14; 18) chromosome translocation. Science 226:1097, 1984
193. Bos JL, Verlaan-de Vries M, van der Eb AJ, Janssen JWG, Delwel R, Löwenberg B, Colly LP: Mutations in N-ras predominate in acute myeloid leukemia. Blood 69:1237, 1987
194. Imamura J, Miyoshi I, Koeffler HP: p53 in hematologic malignancies. Blood 84:2412, 1994
195. Denglet R, Münstermann U, Al-Batran S, Hausner I, Faderl S, Nerl C, Emmerich B: Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 89:250, 1995
196. Sainsbury JR, Farndon JR, Needman GK, Malcolm AJ, Harris AL: Epidermal-growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1:1398, 1987
197. Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M: Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 48:161, 1988
198. Slamon DJ, Clark GM, Wong WJ, Levin A, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177, 1987
199. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udoove J, Ullrich A, Press MJ: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707, 1989
200. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC: Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66:1116, 1992
201. Theillet C, Adelaide J, Louason G, Bonnet-Dorion F, Jacquemier J, Adnane J, Longy M, Katsaros D, Sismondi P, Gaudray P: FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer 7:219, 1993
202. Saitoh S, Cunningham J, de Vries EMG, McGovern RM, Schroeder JJ, Hartmann A, Blaszyk H, Wold LE, Schaid D, Sommer SS, Kovach JS: p53 gene mutations in breast cancers in midwestern US women: Null as well as missense-type mutations are associated with poor prognosis. Oncogene 9:2869, 1994
203. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93:1093, 1996
204. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263:12820, 1988
205. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D: Isolation and sequencing of a cDNA coding for he human DF3 breast carcinoma-associated antigens. Proc Natl Acad USA 85:2320, 1988
206. Thompson JA, Grunert F, Zimmermann W: Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J Clin Lab Anal 5:344, 1991
207. Jung S, Schluesener HJ: Human T lymphocytes recognize a peptide of single point-mutated, oncogeneic ras proteins. J Exp Med 173:273, 1991
208. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G: Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 81:1369, 1993
209. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87:3587, 1996
210. ten Bosch GJA, Joosten AM, Kessler JH, Melief CJM, Leeksma OC: Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88:3522, 1996
211. Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet JG, Choppin J: Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 27:2066, 1997
212. Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethe B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229, 1995
213. Barnd DL, Lan MS, Metzgar RS, Finn OJ: Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86:7159, 1989
214. Ionnanides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptide. J Immunol 151:3963, 1993
215. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA: In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54:16, 1994
216. Houbiers JGA, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJH, Brand A, Momburg F, Kast WM, Melief CJM: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 23:2072, 1993
217. Alexander-Miller MA, Leggatt GR, Berzofsky JA: Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 93:4102, 1996
218. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H: Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 186:229, 1997
219. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271, 1991
220. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317, 1996
221. Inaba K, Metlay JP, Crowley MT, Steinman RM: Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, major histocompatibility complex-restricted T cells in situ. J Exp Med 172:631, 1990
222. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24:605, 1994
223. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, DeLeo AB : Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1:1297, 1995
224. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87, 1996
225. Celluzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183:283, 1996
226. Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918, 1996
227. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccinations of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
228. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A: Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 85:2680, 1995
229. Fisk B, Blevins TL, Taylor Wharton J, Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109, 1995
230. Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet J-G, Choppin J: Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 27:2066, 1997
231. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, Agarwala V, Barrett AJ: Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90:2529, 1997
232. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cane er-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad USA 92:432, 1995
233. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ: Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155:4486, 1995
234. Doménech N, Henderson RA, Finn OJ: Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155:4766, 1995
235. Storkus WJ, She HJ III, Salter RD, Lotze MT: Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 14:94, 1993
236. Bernhardt H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA: Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral Wood. Cancer Res 55:1099, 1995
237. Szabolcs P, Moore MAS, Young JW: Expansion of immuno-stimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J Immunol 154:5851, 1995
238. Siena S, Di NicolaM, Bregni M, Mortarini R, Anichini A, Lombardi L, Ravagnani F, Parmiani G, Gianni AM: Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 23:1463, 1995
239. Fisch P, Kohler G, Garbe A, Herbst B, Wider D, Kohler H, Schaefer H, Mertelsmann R, Brugger W, Kanz L: Generation of antigen-presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients. Eur J Immunol 26:595, 1996
240. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ: Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 56:3763, 1996
241. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P: Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 56:5672, 1996
242. Aicher A, Westermann J, Cayeux S, Willimsky G, Daemen K, Blankenstein T, Uckert W, Dörken B, Pezzutto A: Successful retroviral mediated transduction of a reporter gene in human dendritic cells: Feasibility of therapy with gene-modified antigen presenting cells. Exp Hematol 25:39, 1997
243. Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, Glaspy JA, Economou JS: Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adeno virus-transduced murine dendritic cells. Cancer Res 57:2865, 1997
244. Wan Y, Bramson J, Carter R, Graham F, Gauldie J: Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Human Gene Ther 8:1355, 1997
245. Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R, Dubinett S, Glaspy J, McBride WH, Economou JS: A comparison of gene transfer methods in human dendritic cells. Cancer Gen Ther 4:17, 1997
246. Slavin S, Naparstek E, Nagler A, Ackerstein A, Drakos P, Kapelushnik Y, Brautbar C, Or R: Cell mediated immunotherapy (CMI) for the treatment of malignant hematological diseases in conjunction with autologous bone marrow tranplantation (ABMT). Blood 82:292a, 1993 (abstr, suppl 1)
247. Bonini C, Ferrari G, Verzeletti PS, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversai C, Bordignon C: HSV-tk gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719, 1997